2021 nominations are closed, and we are now accepting nominations for the 2022 awards.
Thank you for your interest in nominations for the HFC/HFSA joint SBR awards, recognizing top PI’s, Study Coordinators, and Sites. 2021 nominations are closed, and we are now accepting nominations for the 2022 awards.
Our goal is to identify and promote the work of those who are outstanding participants in HF clinical trials. We are particularly interested in recognizing the diverse population of scientists across under-represented minority groups, sex, ethnicity, geographic location, and economic landscapes. The nominations will be reviewed by the HFC Research Network Working Group in the first two quarters of 2022. Winners will be notified summer 2022 and will receive a $500 award for the HFSA Scientific Annual Meeting. The awards will be presented at the meeting Sept 30-Oct 3, 2022.
To be eligible, nominees should have meaningful involvement in a clinical trial listed on ClinTrials.gov. Nominees’ range of accomplishments can include meritorious achievement in trial design, execution/enrollment, and/or reporting scientific content in a trial in which they were involved; as well as challenges encountered and steps taken to meet the challenge in a trial.
Metrics to consider include number of subjects enrolled, enrollment of under-represented group/diverse populations, diverse study groups, data quality, retention, and citizenship (helping other sites participate, participating in trial activities, committee participation, patient recognition and education, dissemination of results). This year we will include overcoming challenges, which may include the impact of COVID-19.
The number of awards is not fixed, and will be determined by the quality of the applicant pool.